Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD FRCPC, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Arleigh McCurdy, MD BSc, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Rami Kotb, MD, Darrell J White, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Anthony Reiman, MD, Fernando Camacho, PhD, Molei Fu, Engin Gul, BSc, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-141087

Published: 2020

Journal Articles

Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort

Hira S Mian, MD, C. Tom Kouroukis, MDMSc,FRCPC, Gregory R Pond, PhD PStat, Hsien Seow, PhD, Jonathan Sussman, MD FRCPC, MSc

Blood (2019) 134 (Supplement_1): 268.

https://doi.org/10.1182/blood-2019-121672

Published: 2019

Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD, Nizar Bahlis, MD, Christopher P. Venner, Arleigh McCurdy, MD, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Darrell J White, MD, Rami Kotb, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Tony Reiman, MD, Fernando Camacho, Julia Dobbin, Molei Fu, Engin Gul, BS, MBA, Donna E Reece, MD

Blood (2019) 134 (Supplement_1): 3121.

https://doi.org/10.1182/blood-2019-124457

Published: 2019

Journal Articles

Estimating the Need for Complex Malignant Hematologists in Ontario Using Monte Carlo Simulation

Jonathan Wang, MASc, Andre C. Schuh, MD FRCPC, Deanna Wu, MBA, Christopher N. Bredeson, MD MSc, FRCPC, Jacinta Meharchand, MD FRCPC, Lisa Favell, MBA, Louis Fu, MISt, Kelly J. Woltman, MA, C. Tom Kouroukis, MDMSc,FRCPC

Blood (2017) 130 (Supplement 1): 3397.

https://doi.org/10.1182/blood.V130.Suppl_1.3397.3397

Published: 2017

Journal Articles

Improved Survival in Overweight and Obese Patients with Non-Hodgkin's Lymphoma Treated with Rituximab Containing Chemotherapy for Curative Intent

James K R Stevenson, MD MSc, Lucy Qiao, MS, MPH, Kelvin Chan, MD PhD, Jaclyn Beca, MSc, Wanrundee Isaranuwatchai, PhD, Helen Guo, BS, Deborah Schwarz, PhD, Jessica Arias, BA, MACP, Scott Gavura, BSPharm, MBA, C. Tom Kouroukis, MDMSc,FRCPC, Matthew Cheung, MD MS, FRCP

Blood (2017) 130 (Supplement 1): 1557.

https://doi.org/10.1182/blood.V130.Suppl_1.1557.1557

Published: 2017

Journal Articles

HBV Care Map for Patients Receiving Anti-CD20 Therapy

Zachary Liederman, MD, Neil Berinstein, MD, Michael Crump, MD, Jessica Hwang, MD MPH, Harry L.A. Janssen, PhD MD, C. Tom Kouroukis, MDMSc,FRCPC, Patricia Leung, Anna Lok, MD, Colina Yim, Andrew D. Zelenetz, MD PhD, Kelvin Chan, MD PhD, Jordan Feld, MD MPH, Lisa K. Hicks, MD MSc

Blood (2017) 130 (Supplement 1): 4697.

https://doi.org/10.1182/blood.V130.Suppl_1.4697.4697

Published: 2017

NARROW

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Estimating the Need for Complex Malignant Hematologists in Ontario Using Monte Carlo Simulation

Improved Survival in Overweight and Obese Patients with Non-Hodgkin's Lymphoma Treated with Rituximab Containing Chemotherapy for Curative Intent

HBV Care Map for Patients Receiving Anti-CD20 Therapy

Email alerts

ASH Publications

American Society of Hematology

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Estimating the Need for Complex Malignant Hematologists in Ontario Using Monte Carlo Simulation

Improved Survival in Overweight and Obese Patients with Non-Hodgkin's Lymphoma Treated with Rituximab Containing Chemotherapy for Curative Intent

HBV Care Map for Patients Receiving Anti-CD20 Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only